# GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

> **NCT01384383** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 248 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** GS-5885
- **DRUG:** GS-9451
- **DRUG:** RBV
- **DRUG:** PEG

## Key facts

- **NCT ID:** NCT01384383
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2014-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01384383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01384383, "GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01384383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*